• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

磷酸化特异性流式：聚焦于靶标。

Phospho-specific flow: fixating on the target.

机构信息

Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.

出版信息

Clin Cancer Res. 2012 Mar 15;18(6):1493-5. doi: 10.1158/1078-0432.CCR-11-3266. Epub 2012 Feb 2.

DOI:10.1158/1078-0432.CCR-11-3266
PMID:22302900
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3306466/
Abstract

Targeted therapies are all the rage in oncology research these days. The problem remains as to how to confirm that the target is actually being hit in vivo. This report describes the application of phospho-specific flow cytometry to establish in vivo target inhibition in real time.

摘要

如今，肿瘤学研究中靶向治疗风靡一时。问题仍然在于如何确认靶标在体内确实被击中。本报告介绍了应用磷酸化特异性流式细胞术实时建立体内靶标抑制的方法。

相似文献

1
Phospho-specific flow: fixating on the target.磷酸化特异性流式：聚焦于靶标。
Clin Cancer Res. 2012 Mar 15;18(6):1493-5. doi: 10.1158/1078-0432.CCR-11-3266. Epub 2012 Feb 2.
2
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.在一项将 mTOR 抑制剂依维莫司与强化化疗联合用于 AML 原始细胞的临床试验中，对 S6 核糖体蛋白磷酸化的单细胞药效学监测。
Clin Cancer Res. 2012 Mar 15;18(6):1716-25. doi: 10.1158/1078-0432.CCR-11-2346. Epub 2011 Dec 13.
3
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.西罗莫司增强高危急性髓系白血病患者的缓解诱导和 mTORC1 靶向抑制。
Invest New Drugs. 2018 Aug;36(4):657-666. doi: 10.1007/s10637-018-0585-x. Epub 2018 Apr 2.
4
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.多机构比较米托蒽醌、依托泊苷和阿糖胞苷与高剂量阿糖胞苷和米托蒽醌治疗复发或难治性急性髓系白血病患者的疗效。
Am J Hematol. 2020 Aug;95(8):937-943. doi: 10.1002/ajh.25838. Epub 2020 May 8.
5
Salvaging AML with CLAG: novel option, or more of the same?使用CLAG挽救急性髓系白血病：新选择，还是老一套？
Leuk Res. 2011 Mar;35(3):297-8. doi: 10.1016/j.leukres.2010.10.015. Epub 2010 Nov 11.
6
Facts about FCE (fludarabine, cytarabine, etoposide) in acute myeloid leukemia.关于氟达拉滨、阿糖胞苷、依托泊苷（FCE）治疗急性髓系白血病的事实。
Acta Haematol. 2014;131(4):200-1. doi: 10.1159/000355134. Epub 2013 Nov 27.
7
Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.米托蒽醌联合依托泊苷及阿糖胞苷持续输注进行强化序贯化疗用于既往接受过治疗的急性髓性白血病
Blood. 1991 May 1;77(9):1894-900.
8
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.雷帕霉素靶蛋白抑制剂西罗莫司与MEC化疗用于复发难治性急性髓系白血病的I期研究。
Clin Cancer Res. 2009 Nov 1;15(21):6732-9. doi: 10.1158/1078-0432.CCR-09-0842. Epub 2009 Oct 20.
9
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.雷帕霉素哺乳动物靶点抑制剂CCI-779单独使用或与化疗联合使用对人前列腺癌细胞及异种移植瘤的作用。
Cancer Res. 2005 Apr 1;65(7):2825-31. doi: 10.1158/0008-5472.CAN-04-3137.
10
Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.孕期难治性急性髓系白血病采用维奈克拉、大剂量阿糖胞苷和米托蒽醌治疗。
Br J Haematol. 2021 Jan;192(2):e60-e63. doi: 10.1111/bjh.17220. Epub 2020 Nov 21.

本文引用的文献

1
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.在一项将 mTOR 抑制剂依维莫司与强化化疗联合用于 AML 原始细胞的临床试验中，对 S6 核糖体蛋白磷酸化的单细胞药效学监测。
Clin Cancer Res. 2012 Mar 15;18(6):1716-25. doi: 10.1158/1078-0432.CCR-11-2346. Epub 2011 Dec 13.
2
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum.单细胞质谱流式细胞术分析人类造血连续统中的免疫和药物反应差异。
Science. 2011 May 6;332(6030):687-96. doi: 10.1126/science.1198704.
3
Flow cytometric analysis of cell signaling proteins.细胞信号蛋白的流式细胞术分析
Methods Mol Biol. 2011;717:155-69. doi: 10.1007/978-1-61779-024-9_9.
4
Protein Interactions Captured by Chemical Cross-linking: One-Step Cross-linking with Formaldehyde.通过化学交联捕获的蛋白质相互作用：与甲醛的一步交联
CSH Protoc. 2007 Apr 1;2007:pdb.prot4634. doi: 10.1101/pdb.prot4634.
5
mTOR: from growth signal integration to cancer, diabetes and ageing.mTOR：从生长信号整合到癌症、糖尿病和衰老。
Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35. doi: 10.1038/nrm3025. Epub 2010 Dec 15.
6
Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.单细胞分析确定了髓系恶性肿瘤中异常的STAT5激活，并与特定的临床和生物学特征相关。
Cancer Cell. 2008 Oct 7;14(4):335-43. doi: 10.1016/j.ccr.2008.08.014.
7
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.血浆抑制活性（PIA）：一项药效学分析揭示了对FLT3抑制剂细胞毒性反应基础的见解。
Blood. 2006 Nov 15;108(10):3477-83. doi: 10.1182/blood-2006-04-015743. Epub 2006 Jul 20.
8
mTOR regulates cell survival after etoposide treatment in primary AML cells.mTOR在原发性急性髓系白血病细胞中调节依托泊苷治疗后的细胞存活。
Blood. 2005 Dec 15;106(13):4261-8. doi: 10.1182/blood-2004-11-4468. Epub 2005 Sep 8.
9
Single cell profiling of potentiated phospho-protein networks in cancer cells.癌细胞中增强的磷酸化蛋白质网络的单细胞分析
Cell. 2004 Jul 23;118(2):217-28. doi: 10.1016/j.cell.2004.06.028.
10
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.ZD1839（一种选择性口服表皮生长因子受体酪氨酸激酶抑制剂）用于五种选定实体瘤类型患者的I期安全性、药代动力学和药效学试验。
J Clin Oncol. 2002 Nov 1;20(21):4292-302. doi: 10.1200/JCO.2002.03.100.